A Case of Colchicine Toxicity Presenting With Euglycemic Diabetic Ketoacidosis

Colchicine has a narrow therapeutic window and a high risk of toxicity when co-administered with CYP3A4 inhibitors and P-glycoprotein inhibitors. Colchicine toxicity is associated with various metabolic disturbances and can cause multiorgan failure and death. However, to our knowledge, there are no...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-05, Vol.15 (5), p.e39063
Main Authors: Delshad, Sean D, Kleiber, Angela
Format: Article
Language:English
Subjects:
Abdomen
Acidosis
Blood
Cardiovascular disease
Case reports
COVID-19
Diabetes
Diabetic ketoacidosis
Diarrhea
Electrolytes
Emergency medical care
Glycoproteins
Internal Medicine
Ischemia
Metabolism
Pneumonia
Tomography
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colchicine has a narrow therapeutic window and a high risk of toxicity when co-administered with CYP3A4 inhibitors and P-glycoprotein inhibitors. Colchicine toxicity is associated with various metabolic disturbances and can cause multiorgan failure and death. However, to our knowledge, there are no documented reports of colchicine toxicity initially presenting as euglycemic diabetic ketoacidosis (DKA). We present a case of colchicine toxicity with concomitant euglycemic DKA in a man with long-term colchicine use who was also prescribed clarithromycin and dapagliflozin.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.39063